Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[VEPA therapy in B-lymphoma].

M Shimoyama, K Minato, T Takenaka

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |March 1, 1986
    PubMed
    Summary

    VEPA therapy shows high effectiveness for B-lymphoma patients. This treatment achieved a 79.2% complete remission rate and significant long-term survival in previously untreated adults.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Tirabrutinib hydrochloride for B-cell lymphomas.

    Drugs of today (Barcelona, Spain : 1998)·2021
    Same author

    Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.

    Blood cancer journal·2017

    Area of Science:

    • Oncology
    • Hematology
    • Clinical Pharmacology

    Context:

    • B-lymphoma is a significant hematologic malignancy.
    • Treatment options for B-lymphoma require continuous evaluation.
    • VEPA therapy is an emerging treatment modality.

    Purpose:

    • To evaluate the efficacy and outcomes of VEPA therapy in adult patients with B-lymphoma.
    • To determine the complete remission rate and long-term survival associated with VEPA therapy.
    • To assess the curability of Stage II B-lymphoma using VEPA therapy.

    Summary:

    • A study involving 48 previously untreated adult B-lymphoma patients demonstrated the effectiveness of VEPA therapy.
    • The therapy resulted in a 79.2% complete remission rate.
    • After 4 years, 48% of patients remained alive, with approximately 90% of Stage II patients expected to be cured.

    Related Experiment Videos

    Impact:

    • VEPA therapy presents a highly effective treatment option for B-lymphoma.
    • The findings suggest potential for improved patient survival and cure rates.
    • Further research into VEPA therapy's role in B-lymphoma management is warranted.